Skip to main content
Innate Pharma S.A. (EPA:IPH)
France flag France · Delayed Price · Currency is EUR
1.178
+0.022 (1.90%)
Apr 28, 2026, 5:35 PM CET

Innate Pharma Revenue

In the year 2025, Innate Pharma had annual revenue of 9.01M EUR, down -55.25%. Innate Pharma had revenue of 4.14M in the half year ending December 31, 2025, a decrease of -80.67%.

Revenue
9.01M
Revenue Growth
-55.25%
P/S Ratio
12.27
Revenue / Employee
55.25K
Employees
174
Market Cap
110.53M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20259.01M-11.12M-55.25%
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
MaaT Pharma 4.52M
Adocia 3.85M
ABIONYX Pharma 4.10M
Valerio Therapeutics Société anonyme 1.83M
OSE Immunotherapeutics 1.78M
Sensorion 5.81M
Transgene 7.21M
Fermentalg 13.38M
Revenue Rankings

Innate Pharma News

More News